Peter Marks

Company: FDA

Job title: Director, CBER

Seminars:

Virtual: Rare Disease Gene Therapy Development: Where Has It Been and Where Is It Going? 8:30 am

Comparing progress in rare disorders in vivo with developments seen in CAR-T and ex vivo cell modified gene therapies Where are the current bottlenecks for gene therapy approvals? Addressing FDA’s outlook for gene therapy in 2022Read more

day: Day One